Abstract
Obesity is a highly prevalent complex trait that raises the risk of other chronic diseases such as type 2 diabetes, certain cancers, sleep apnea, and cardiovascular disease, and shortens lifespan. Clinical intervention studies focused on weight loss and epidemiological studies of obesity indicate that genetic variation may modify the relationship between lifestyle behaviors and weight loss or weight gain. Similar observations have also emerged from pharmacogenetic studies. The literature includes several reports from these studies, but few examples of interactions have been adequately replicated. In this review we introduce the topics of population genetics and gene x environment interaction research. We also provide a systematic review of the published literature on gene x lifestyle (physical activity and dietary factors) and gene x drug interactions in relation to obesity. Finally, we overview the scope and findings from these studies and discuss some of their strengths and limitations.
Keywords: Genetic, gene x drug interaction, gene x lifestyle interaction, nutrition, nutriogenomics, obesity, pharmacogenetics, physical activity, cardiovascular disease, type 2 diabetes mellitus
Current Vascular Pharmacology
Title: Gene-Lifestyle and Gene-Pharmacotherapy Interactions in Obesity and Its Cardiovascular Consequences
Volume: 9 Issue: 4
Author(s): Paul W. Franks and Alaitz Poveda
Affiliation:
Keywords: Genetic, gene x drug interaction, gene x lifestyle interaction, nutrition, nutriogenomics, obesity, pharmacogenetics, physical activity, cardiovascular disease, type 2 diabetes mellitus
Abstract: Obesity is a highly prevalent complex trait that raises the risk of other chronic diseases such as type 2 diabetes, certain cancers, sleep apnea, and cardiovascular disease, and shortens lifespan. Clinical intervention studies focused on weight loss and epidemiological studies of obesity indicate that genetic variation may modify the relationship between lifestyle behaviors and weight loss or weight gain. Similar observations have also emerged from pharmacogenetic studies. The literature includes several reports from these studies, but few examples of interactions have been adequately replicated. In this review we introduce the topics of population genetics and gene x environment interaction research. We also provide a systematic review of the published literature on gene x lifestyle (physical activity and dietary factors) and gene x drug interactions in relation to obesity. Finally, we overview the scope and findings from these studies and discuss some of their strengths and limitations.
Export Options
About this article
Cite this article as:
W. Franks Paul and Poveda Alaitz, Gene-Lifestyle and Gene-Pharmacotherapy Interactions in Obesity and Its Cardiovascular Consequences, Current Vascular Pharmacology 2011; 9 (4) . https://dx.doi.org/10.2174/157016111796197233
DOI https://dx.doi.org/10.2174/157016111796197233 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypothyroidism and Nephrotic Syndrome: Why, When and How to Treat
Current Vascular Pharmacology Catalytic Nanomedicine. Cu/TiO<sub>2</sub>–SiO<sub>2</sub> Nanoparticles as Treatment of Diabetic Foot Ulcer: A Case Report
Current Nanomedicine Pegaptanib Sodium for the Treatment of Proliferative Diabetic Retinopathy and Diabetic Macular Edema
Current Diabetes Reviews Novel Insights into Vascular Repair Mechanisms
Current Pharmaceutical Design Demystifying the ACE Polymorphism: From Genetics to Biology
Current Pharmaceutical Design Mass Spectrometry, Proteomics, Data Mining Strategies and Their Applications in Infectious Disease Research.
Anti-Infective Agents in Medicinal Chemistry Drug Therapy for Behavioral and Psychological Symptoms of Dementia
Current Neuropharmacology Evolution of Exenatide as a Diabetes Therapeutic
Current Diabetes Reviews Establishing Maternal Tolerance: The Role of Regulatory T Cells (Tregs) in Pregnancy and Pathophysiology of Preeclampsia
Current Women`s Health Reviews Blood Pressure Lowering Treatment in Patients with Carotid Artery Stenosis
Current Hypertension Reviews Ghrelin as a Potential Anti-Obesity Target
Current Pharmaceutical Design Stress and Aging
Current Genomics Epigenetic control of cardiovascular health by nutritional polyphenols involves multiple chromatin-modifying writer-reader-eraser proteins
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design Detrimental Effects of Hyperglycemia in Acute Coronary Syndromes: from Pathophysiological Mechanisms to Therapeutic Strategies
Mini-Reviews in Medicinal Chemistry Antioxidant Activity, α-glucosidase Inhibitory Activity and Chemoprotective Properties of Rhododendron brachycarpum Leaves Extracts
Current Pharmaceutical Biotechnology Macrovascular Complications of Type 2 Diabetes Mellitus
Current Vascular Pharmacology Natalizumab Modifies Catecholamines Levels Present in Patients with Relapsing- Remitting Multiple Sclerosis
Current Pharmaceutical Design Subject Index To Volume 3
Vascular Disease Prevention (Discontinued) Overview on Thioredoxin-Interacting Protein (TXNIP): A Potential Target for Diabetes Intervention
Current Drug Targets